Clinical Trials
MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
Triastek Opens a New Chapter for Digital Formulation Development and Intelligent Pharmaceutical Manufacturing 09/02/2021 — NANJING, China — (BUSINESS WIRE) Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing […]
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
– Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – – Agreement includes royalties of up […]
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated disease 11/12/2020 — TOKYO & MUNICH — (BUSINESS WIRE) Daiichi Sankyo Company, […]
Takashi Nagao Appointed President and Chief Executive Officer of Medicago
Medicago prepares for the commercialization of the company’s vaccine candidates 04/12/2020 — QUEBEC CITY, Québec — (BUSINESS WIRE) Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi […]
Medicago Announces Positive Phase 1 Results for Its #COVID-19 Vaccine Candidate
100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses 11/11/2020 — QUEBEC CITY, Quebec — (BUSINESS WIRE) Medicago, […]
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
29/09/2020 — NEW YORK, LONDON, & PARIS — (BUSINESS WIRE) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on […]
Former World Head of State to Address Attendees at Everbridge’s COVID-19: Road to Recovery (R2R) Symposium, Joining Dr. Anthony Fauci, Sir Richard Branson, and Dr. Sanjay Gupta as Keynotes, October 14-15, 2020
Former World Head of State to Address Attendees at Everbridge’s COVID-19: Road to Recovery (R2R) Symposium, Joining Dr. Anthony Fauci, Sir Richard Branson, and Dr. Sanjay Gupta as Keynotes, October […]
Ormendes SA – First Published Clinical Trial In COVID-19 Suggests Role of Live Biotherapeutic Candidate in Seriously Ill Patients
Italian clinical study finds combined strains of live bacteria reduced diarrhea and prevented progression of symptoms in hospitalized COVID19-patients 11/09/2020 — LAUSANNE, Switzerland — (BUSINESS WIRE) Ormendes SA is proud […]
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other safety concerns […]
Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate
Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate First doses administered to human volunteers 15/07/2020 — QUEBEC CITY — (BUSINESS WIRE) Medicago, a biopharmaceutical company headquartered in […]
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients. At […]
Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress
18/06/2020 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation in the European Association for Cancer […]
Medicago Announces Production of a Viable Vaccine Candidate for COVID-19
The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology Medicago’s platform can produce both vaccine and antibody candidates against COVID-19 disease […]
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
10/02/2020 — NEW YORK — (BUSINESS WIRE) Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, […]
Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies
19/11/2019 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science […]
Janssen Receives Positive CHMP Opinion for Spravato® (esketamine) Nasal Spray for Adults with Treatment-Resistant Major Depressive Disorder
If approved by the European Commission, esketamine nasal spray will offer the first new mechanism of action in 30 years to treat major depressive disorder (MDD) In the phase III […]
Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial
09/09/2019 — MENLO PARK, Calif. & PARIS — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has entered into a research […]
Merck to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Not intended for UK and U.S. based media Company to present 39 abstracts, including data on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib Long-term data and real-world evidence […]
Frank Schestag, PhD, Joins Proteintech as Commercial Director in Europe
10/07/2019 — ROSEMONT, Ill. — (BUSINESS WIRE) Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing leadership to the sales and […]
Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe
Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A new CNS-focused company, Arvelle received one of […]
First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System and Enrolls in Post-Market Registry
Investigator initiated EXCeL Registry will assess safety and abdominal aortic aneurysm treatment success in patients with challenging anatomies 17/09/2018 — FLAGSTAFF, Ariz. — (BUSINESS WIRE) W. L. Gore & Associates, […]
BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Regulatory Approvals In-Process; New Record Date to be Set Shortly 17/09/2018 — ALAMEDA, Calif. — (BUSINESS WIRE) BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, […]
CorFlow Completes USD 9.7M in Seed Funding
14/09/2018 — BAAR, Switzerland — (BUSINESS WIRE) CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ financing round. To date, and since the CorFlow […]
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target The collaboration will investigate a new therapeutic approach that […]
Phase III Study using 22nd Century’s SPECTRUM® Research Cigarettes Demonstrates Immediate Reduction to Very Low Nicotine is Most Likely to Lead to Less Harm
“Minimally or non-addictive Very Low Nicotine cigarettes are the ultimate harm reduction strategy” 06/10/2017 — CLARENCE, N.Y. — (BUSINESS WIRE) 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology […]
Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research
Helps companies accelerate the development of new medications by reducing the failure rate during the clinical phase 21/06/2017 — STRASBOURG, France — (BUSINESS WIRE) Bionext, a bioinformatics company, announces today […]
Latest clinical research confirms that IQOS reduces smoker exposure to select harmful chemicals as compared to cigarette smoke
Studies conducted to date clearly indicate that IQOS is likely to present less risk of harm compared to smoking 27/03/2017 — LAUSANNE, Switzerland — (BUSINESS WIRE) Philip Morris International Inc. […]
LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
06/01/2017 — LES ULIS, France — (BUSINESS WIRE) LFB S.A., announced that its Biologic License Application (BLA), requesting marketing approval of Coagulation Factor VIIa (Recombinant) as a treatment for congenital […]
ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations
Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial 06/12/2016 — […]
Senseonics Reports Topline Accuracy Results from U.S. Pivotal Study of Eversense CGM System.
Topline Accuracy of 8.8% MARD (Mean Absolute Relative Difference) over 90 Days. 09/08/2016 — GERMANTOWN, Md. — (BUSINESS WIRE) Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development […]